Eli Lilly and Company (LLY)
Eli Lilly Booms, Then Busts: Stellar Guidance vs Hims Undercut
In its latest earnings report, Eli Lilly and Company NYSE: LLY once again showed why it has become by far one of the world's most valuable healthcare stocks. Year-to-date, Eli Lilly's market capitalization exceeds $900 billion.
Eli Lilly (LLY) is a Top-Ranked Growth Stock: Should You Buy?
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Eli Lilly: Positives Outweigh The Concerns
Eli Lilly and Company's price jump following its latest earnings release is completely justified going by both the performance and guidance. Both LLY revenue and EPS growth exceeded guidance, despite a cut in Zepbound's price in Q4 2025. The guidance for 2026 also makes the stock attractive. However, a fuller impact of price cuts is expected to be visible only a quarter later, along with a possible impact of an acquisition on its earnings, indicating some caution is warranted for LLY stock.
The Metabolic Split: Why Eli Lilly Soars as Novo Stumbles
The first week of February 2026 will be remembered as the day the pharmaceutical sector's most famous partnership officially dissolved. For years, Eli Lilly and Company NYSE: LLY and Novo Nordisk A/S NYSE: NVO traded in lockstep, their stock charts nearly identical as they raced to supply the world with weight-loss medicines.
Eli Lilly and Company (LLY) Q4 2025 Earnings Call Transcript
Eli Lilly and Company (LLY) Q4 2025 Earnings Call Transcript
Eli Lilly Stock Soars While Novo Nordisk Sinks—Why the Weight-Loss Leaders Are Headed in Opposite Directions
There's a growing divergence between the shares of rival weight-loss drugmakers Eli Lilly and Novo Nordisk.
Eli Lilly Stock Soars While Novo Nordisk Sinks—Why the Weight-Loss Leaders Are Headed in Opposite Directions
There's a growing divergence between the shares of rival weight-loss drugmakers Eli Lilly and Novo Nordisk.
Here's What Key Metrics Tell Us About Lilly (LLY) Q4 Earnings
While the top- and bottom-line numbers for Lilly (LLY) give a sense of how the business performed in the quarter ended December 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Lilly Stock Jumps After Q4 Earnings Beat and Strong 2026 Guidance
LLY beats Q4 earnings and sales estimates as Mounjaro and Zepbound surge. Shares jump on stronger-than-expected revenue and EPS outlook for 2026.
Eli Lilly Stock Eyes Best Day Since October After Quarterly Beat
Eli Lilly And Co ( NYSE:LLY) stock is up 7.7% to trade at $1,080.69 at last glance, after the pharmaceutical name reported a top- and bottom-line beat for the fourth quarter and issued an upbeat forecast for 2026.
Eli Lilly shares soar after Q4 beat, strong forecast on weight-loss drugs
Eli Lilly and Co (NYSE:LLY) shares surged 9.5% in Wednesday morning trading after the drugmaker posted fourth-quarter results that topped Wall Street expectations and issued a robust forecast for 2026, fueled by soaring demand for its weight‑loss treatments. The company reported revenue of $19.29 billion for the fourth quarter, up 43% from a year earlier and well above analysts' estimate of $18.01 billion.
3 Reasons A Pullback In Eli Lilly Stock Is Likely
Eli Lilly (LLY) is encountering challenges. Even well-established companies are not immune to corrections.
